Oral cancer is the sixth most common cancer in the world, with about three hundred thousand new cases being registered every year. Currently, the treatments available for this disease presents several problems related to the physico-chemical and pharmacokinetic characteristics of the drugs, which results, mainly, in a low efficiency of the method. In addition, the therapies offered presents high economic cost.
The proposed technology offers an effective method for the administration of curcumin by a mucoadhesive release system, which prolongs the residence time of the drug at the absorption site, resulting in greater treatment efficiency. In addition, this drug is composed of a molecule of natural origin, which has shown potential to inhibit the nuclear factor kappa-beta, main contributor to the development of oral cancer.
Agência Unesp de Inovação
Tel: +55 11 5627.0696